Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT03986073
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Registry
-
NCT03986073
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03986073. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-01 (actual); primary completion 2020-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- TQ-F3083 capsule 10 mg
- Intervention (Drug)
- TQ-F3083 capsule 20 mg
- Intervention (Drug)
- TQ-F3083 blank analog capsule
- Intervention (Drug)
- TQ-F3083 blank analog capsule
- Intervention (Drug)
- Linagliptin blank analog tablet
- Intervention (Drug)
- Linagliptin tablet
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Record details
- Record id
cardio:ct-nct03986073- Content hash
baa41b5110255bacc35a174ee62c72deae8ed80cd2e7851c78e49a6491be1c32